Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report

Abstract: Embryonal rhabdomyosarcoma (ERMS) has a low prevalence, poor prognosis, and limited treatment efficacy. We report a case of an 18-year-old male whose disease relapsed in the abdominal cavity after a testicular ERMS curative resection. The patient received eight sequential cycles of rescue therapy using cisplatin and isocyclophosphamide in combination with a vascular targeted drug, Endostar. The therapeutic effect of the combination regimen has been evaluated for complete response. This is the first case to report using Endostar and chemotherapy in relapsed ERMS, and the curative effect results in complete response. Endostar, a new vascular targeted drug, combined with chemotherapy may play a synergistic role and provide a reference for the treatment of ERMS.

Keywords: embryonal rhabdomyosarcoma, metastasis, complete response, endogenous angiogenesis inhibitor

Introduction

Embryonal rhabdomyosarcoma (ERMS), a rare category of soft tissue sarcoma (STS), originates in the mesenchymal tissue. There are three major histologic subtypes of rhabdomyosarcoma (RMS), embryonal, alveolar, and pleomorphic, and the first two are also called nonpleomorphic RMS. The head and neck region is the most affected site, followed closely by the genitourinary tract, in which ~25% of cases occur. Surgery is the best method for removing early-stage tumors; however, there remains a high risk of recurrence or distant metastasis afterward. Despite clinical trials demonstrating the efficacy of many types of chemotherapy, ERMS has a low objective response rate to cytotoxic drugs and a poor long-term prognosis with short progression-free survival (PFS).

Endostar was first approved by the China Food and Drug Administration in 2005 for the treatment of non-small-cell lung cancer. It is a broad-spectrum endogenous angiogenesis inhibitor and primarily acts on a5b1 and avb3 integrins, surface nucleolin, caveolin-1, glypicans-1 and 4, MMP-2, and the VEGFR-2 spectrum. Endostar selectively acts on microvascular endothelial cells and plays antiproliferation, antimigration, and apoptosis-promoting roles. In addition, a multicenter Phase II clinical trial was launched on April 20, 2017 to compare the efficacy and safety of Endostar combined with chemotherapy vs chemotherapy alone in patients with stage IV STSs (NCT03121833). Thus, Endostar combined with chemotherapy may theoretically improve patient prognosis.

Here, we report a case of an 18-year-old male with ERMS distant metastasis after surgery who was treated with chemotherapy combined with Endostar, and the patient showed complete response (CR) after eight sequential cycles.
Case report
An 18-year-old Chinese man arrived at our hospital with fever, abdominal distension, abdominal pain, anorexia, and weight loss of 10 kg over the last 6 months. Upon physical examination, the patient had a Karnofsky performance score of 70.

Six months previously, the patient had undergone testicular orchietomy. We learned about the procedure from the surgical records. The doctor opened the right scrotum until the right testicle was revealed, and there were multiple solid tumors that presented sarcomatoid changes. The tumors had invaded the epididymis and surrounding spermatic cord upward into the penis and were considered malignant. After obtaining consent from the patient and his family, a radical resection of the tumor was performed. A portion of the tumor was examined, the size of which was 1.5×1.0×0.7 cm, and the tumor was mostly covered with capsules. Under the microscope, concentrated and sparse areas of tumor cells alternated, with an oval shape or short spindles, and the cytoplasm was not obvious. Immunohistochemistry results demonstrated CK(−), Vimentin(+), PLAP(−), CD30(−), SALL4(−), MyoD1(+), Myogenin(+), Desmin(+), CD3(−), CD20(−), Pax-5 and Ki-67(>50%). We did not find evidence of retroperitoneal lymphadenopathy. The histopathological examination of the specimen revealed it to be ERMS T1 N0 M0 (Figure 1). Positron emission tomography (PET)/computed tomography (CT) showed multiple brown fat tissues all over the body and no abnormal metabolism at the operative site, and no tumor tissue was observed after surgery. Unfortunately, he and his family refused adjuvant therapy.

During this hospitalization, we discovered that the abdomen and pelvis had neoplasms, with a diameter of ~31.6×10 cm by CT (Figure 2A). The image shows an abdominal tumor attached to the intestine. There were no other sites of metastasis.

Then, the patient was treated with a cross-line rescue therapy combining cisplatin and isocyclophosphamide and simultaneously with Endostar for a total of eight cycles. The method of administration is described in Table 1. During treatment, the patient experienced chemotherapy-related adverse reactions such as marrow suppression and nausea after two cycles, but the reactions were tolerable without adjusted doses. After the second and fourth cycles, the CT review showed that the abdominal and pelvis neoplasms were significantly reduced (Figure 2B and C). After the eighth cycle, CT indicated that the image was slightly better than the previous CT image (Figure 2D), and the PET/CT showed increased foci of brown adipose tissue that distributed weaker radioactivity all over the body compared with previous scans. There were no significant changes on the right side of the testicular resection area compared with previous PET/CT results. There was also no obvious tumor tissue after treatment (Figure 3). The entire treatment after eight cycles was considered as CR. In addition, there were no severe adverse reactions that appeared during the treatment, and the patient’s symptoms were reduced with a Karnofsky performance score of 90. He has been alive for 19 months since abdominal metastasis.

Discussion
Metastatic ERMS has a high mortality rate and a poor prognosis. The treatment options for non-pleomorphic (alveolar and embryonal) ERMS in the National Comprehensive Cancer Network guidelines do not describe a specific chemotherapy regimen, but emphasize that this disease type is different from other STS systemic chemotherapies, and multidisciplinary combination therapy is recommended.2

Gee et al discovered that vascular endothelial growth factor receptor and vascular endothelial growth factor (VEGF) exist in patients with ERMS.3 Moreover, VEGF has high expression and regeneration in this group.4,5 Unfortunately, VEGF binding to its receptor can promote tumor cell proliferation. Endostar is a broad-spectrum VEGF inhibitor that may inhibit tumor growth in ERMS.6 Although immediate reports are lacking, much of the research on STSs has examined this option. In a study of advanced bone and STSs, Endostar combined with chemotherapy had significant activity toward increasing PFS and improving the clinical benefit rate.7 Teng et al reported that the treatment of a pleural synovial sarcoma patient with combined chemotherapy and Endostar plus sunitinib was effective.8 A retrospective case series study with a total of 71

Figure 1 Histological section with hematoxylin and eosin staining, magnification, ×200. Primarily round and spindle cells, were identified to contain eccentric nuclei and deeply eosinophilic cytoplasm.
patients suffering from advanced STSs suggested that Endostar combined with chemotherapy had a higher disease control rate and longer PFS than traditional chemotherapy.13

For ERMS, it is recommended that vincristine, actinomycin D, cyclophosphamide, isocyclophosphamide, adriamycin, cisplatin, and irinotecan are applicable, but there is no first-line protocol.14,15 The VAC (vincristine, actinomycin D, and cyclophosphamide) and IVA (ifosfamide, vincristine, and actinomycin D) regimens are the most widely used for adjuvant chemotherapy, but patients develop metastatic disease after adjuvant chemotherapy and are treated with multidrug chemotherapy.16 For the treatment of relapsed disease, a clinical trial (NCT01355445) using vincristine, irinotecan, and temozolomide may provide hope for patients with refractory/relapsed rhabdomyosarcoma.

In this study, our patient, who used Endostar combined with cisplatin and isocyclophosphamide, did not follow the routine chemotherapy regimen because in the genetic test results, cis-platinum had a good curative effect and low toxicity. To our surprise, after eight cycles of treatment, he was evaluated as having CR, and PFS was 19 months rather than the average PFS of 13.3 months seen with the routine chemotherapy regimen of vincristine, d-actinomycin, and cyclophosphamide.17 In a study by Liu et al,

**Table 1** Specific chemotherapy of the patient

<table>
<thead>
<tr>
<th>Chemotherapy regimen</th>
<th>Dosage</th>
<th>Delivery route</th>
<th>Time</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endostar</td>
<td>7.5 mg/m²/day</td>
<td>Continuous IV pumping</td>
<td>Days 1–14</td>
<td>Every 21 days</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>30 mg/m²/day</td>
<td>IV</td>
<td>Days 1–3</td>
<td>for eight cycles</td>
</tr>
<tr>
<td>Ifosfamide (Mesna)</td>
<td>1.2 g/m²/day</td>
<td>IV</td>
<td>Days 1–5</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: IV, intravenous.
two patients with relapse or metastasis who were treated with RIO+RPLND+chemotherapy only achieved partial response. To our knowledge, this is the first case to report the successful use of Endostar and chemotherapy with cisplatin and ifosfamide in abdominal cavity relapsed metastasis after testicular ERMS orchectomy. Moreover, the curative effect resulted in CR. Meanwhile, Endostar caused tolerable side effects; its adverse clinical reactions are cardiac reactions. Rarer reactions include mainly skin and accessory allergic reactions and digestive tract reactions. Endostar did not cause cardiotoxicity in our patient, and combined with chemotherapy, Endostar may play a synergistic role in the treatment of ERMS.

Conclusion
Currently, there is no definite protocol for the treatment of metastatic ERMS. Conventional chemotherapy has limited efficacy and poor prognosis. Our case report is the first report using chemotherapy and Endostar, with CR. Endostar, a new vascular targeted drug, combined with chemotherapy may play a synergistic role, but further clinical confirmation is needed.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (No 81702622) and the Army Medical Science and Technology Youth Development Scheme (15QNP005).

Disclosure
The authors report no conflicts of interest in this work.

References

